论文部分内容阅读
本文采用1800mg/d和2400mg/d加巴喷丁治疗疱疹感染后神经痛,7周后对其疗效和安全性进行了多中心、双盲、随机和安慰剂对照研究。将334例患者（年龄18岁以上,平均年龄73岁）分为3组,即安慰剂组、1800mg/d和2400mg/d加巴喷丁治疗组。观察指标采用:1、头痛日记获得平均疼痛分数的改变（第1周与最后第7周相比）;2、每周平均睡眠干扰指数、McGill疼痛问卷调查简表（SF-MPQ）、医师和患者全面印象评分（Clinician and Patient GlobalImpression of Change,CGIC/PGIC）、健康调查简表36（SF-36）。 结果:从第1周开始,加巴喷丁治疗组的疼痛分数有显著降低,7周后安慰剂组之疼痛分数下降15.7％;1800mg/d和2400mg/d加巴喷丁治疗组分别下降34.5％和34.4％。与安慰剂组相比,1800mg/d和
This article uses 1800mg / d and 2400mg / d gabapentin in the treatment of neuralgia after herpes infection, 7 weeks after the efficacy and safety of a multi-center, double-blind, randomized and placebo-controlled study. 334 patients (18 years of age or older, mean age 73 years) were divided into 3 groups: placebo, 1800 mg / day, and gabapentin 2400 mg / day. Observations were taken as follows: 1. The average pain score was changed from the headache diary (week 1 compared with the last 7 weeks); 2. The average weekly sleep disturbance index, the McGill Pain Questionnaire (SF-MPQ) Clinician and Patient Global Impression of Change (CGIC / PGIC), Health Survey Profile 36 (SF-36). Results: The pain scores of gabapentin group were significantly decreased from week 1, and the pain scores of placebo group decreased 15.7% after 7 weeks. The dosages of gabapentin group decreased 34.5% and 34.4% respectively after 1800mg / d and 2400mg / d. Compared with the placebo group, 1800mg / d and